MCID: UTR042
MIFTS: 22

Uterus Leiomyosarcoma

Categories: Reproductive diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Uterus Leiomyosarcoma

MalaCards integrated aliases for Uterus Leiomyosarcoma:

Name: Uterus Leiomyosarcoma 12
Leiomyosarcoma of the Corpus Uteri 55
Leiomyosarcoma of Corpus Uteri 12
Leiomyosarcoma of Uterus 69

Classifications:



External Ids:

Disease Ontology 12 DOID:5289
NCIt 46 C6340
SNOMED-CT 64 447389009
Orphanet 55 ORPHA213625
UMLS via Orphanet 70 C0280631
ICD10 via Orphanet 33 C54.2
UMLS 69 C0280631

Summaries for Uterus Leiomyosarcoma

Disease Ontology : 12 A uterine Corpus sarcoma and leiomyosarcoma and uterine Corpus smooth muscle neoplasm that is located in the smooth muscle of the uterus.

MalaCards based summary : Uterus Leiomyosarcoma, also known as leiomyosarcoma of the corpus uteri, is related to leiomyosarcoma. The drugs Gemcitabine and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include the smooth muscle of the uterus, uterus and smooth muscle.

Related Diseases for Uterus Leiomyosarcoma

Diseases related to Uterus Leiomyosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 leiomyosarcoma 9.8

Symptoms & Phenotypes for Uterus Leiomyosarcoma

Drugs & Therapeutics for Uterus Leiomyosarcoma

Drugs for Uterus Leiomyosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 92)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 3,Phase 2 95058-81-4 60750
2
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
3
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
4
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
5
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
6
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
7
Cyproheptadine Approved Phase 3 129-03-3 2913
8
Bevacizumab Approved, Investigational Phase 3 216974-75-3
9
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2 114977-28-5 148124 9877265
10
Doxil Approved June 1999 Phase 3,Phase 2 31703
11 Alkylating Agents Phase 3,Phase 2
12 Angiogenesis Inhibitors Phase 3,Phase 2
13 Angiogenesis Modulating Agents Phase 3,Phase 2
14 Anti-Bacterial Agents Phase 3,Phase 2
15 Anti-Infective Agents Phase 3,Phase 2
16 Immunosuppressive Agents Phase 3,Phase 2
17 Antimetabolites Phase 3,Phase 2
18 Antimetabolites, Antineoplastic Phase 3,Phase 2
19 Antimitotic Agents Phase 3,Phase 2
20 Antiviral Agents Phase 3,Phase 2
21 Isophosphamide mustard Phase 3,Phase 2 0
22 Adjuvants, Immunologic Phase 3,Phase 2
23 Mitogens Phase 3,Phase 2
24 Topoisomerase Inhibitors Phase 3,Phase 2
25 Endothelial Growth Factors Phase 3,Phase 2
26 Antibiotics, Antitubercular Phase 3,Phase 2
27 Antibodies, Monoclonal Phase 3,Phase 2
28 Immunoglobulins Phase 3,Phase 2
29 Antibodies Phase 3,Phase 2
30
Histamine Phosphate Phase 3 51-74-1 65513
31
Serotonin Phase 3 50-67-9 5202
32 Serotonin Agents Phase 3
33 Serotonin Antagonists Phase 3
34 Gastrointestinal Agents Phase 3
35 Neurotransmitter Agents Phase 3
36 Histamine Antagonists Phase 3
37 Histamine H1 Antagonists Phase 3
38 Dermatologic Agents Phase 3
39 Anti-Allergic Agents Phase 3
40 Antipruritics Phase 3
41
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
42
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
43
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
44
Progesterone Approved, Vet_approved Phase 2 57-83-0 5994
45
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
46
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
47
Etoposide Approved Phase 2 33419-42-0 36462
48
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
49
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
50
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563

Interventional clinical trials:

(show all 46)

# Name Status NCT ID Phase Drugs
1 Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus Completed NCT00002459 Phase 3
2 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
4 Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Active, not recruiting NCT01533207 Phase 3 Docetaxel;Doxorubicin Hydrochloride;Gemcitabine Hydrochloride
5 Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma Terminated NCT01012297 Phase 3 Docetaxel;Gemcitabine Hydrochloride
6 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
7 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Unknown status NCT02203760 Phase 2 Pazopanib plus Gemcitabine;Pazopanib
8 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
9 Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma Unknown status NCT00033709 Phase 2 temozolomide;thalidomide
10 Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT01637961 Phase 2 Alisertib
11 Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy Completed NCT01220609 Phase 2 Ixabepilone
12 Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma Completed NCT02249702 Phase 2 gemcitabine + docetaxel;trabectedin
13 Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT00378911 Phase 2 sunitinib malate
14 Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma Completed NCT00282087 Phase 2 gemcitabine, docetaxel, doxorubicin
15 Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus Completed NCT00379145 Phase 2 trabectedin
16 Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma Completed NCT00101127 Phase 2 docetaxel;gemcitabine hydrochloride
17 Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma Completed NCT00856050 Phase 2 letrozole
18 Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma Completed NCT02131480 Phase 2 Doxorubicin;Trabectedin
19 Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus Completed NCT00025220 Phase 2 Thalidomide
20 Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus Completed NCT00031629 Phase 2 Docetaxel;Gemcitabine Hydrochloride
21 Chemotherapy in Treating Patients With Sarcoma of the Uterus Completed NCT00005643 Phase 2 pegylated liposomal doxorubicin hydrochloride
22 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
23 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2 ziv-aflibercept
24 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
25 Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma Completed NCT00227669 Phase 2 docetaxel;gemcitabine hydrochloride
26 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
27 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
28 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
29 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
30 Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract Completed NCT00003334 Phase 2 paclitaxel;pegylated liposomal doxorubicin hydrochloride
31 Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma Completed NCT00004066 Phase 2 docetaxel;gemcitabine hydrochloride
32 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
33 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
34 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
35 Thalidomide in Treating Patients With Gynecologic Sarcomas Completed NCT00006005 Phase 2 thalidomide
36 Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma Recruiting NCT02428192 Phase 2
37 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Recruiting NCT02601209 Phase 1, Phase 2 Pazopanib Hydrochloride;Sapanisertib
38 Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma Terminated NCT00414076 Phase 2 Letrozole
39 Gemcitabine in Treating Patients With Recurrent or Refractory Cancer of the Uterus Terminated NCT00003316 Phase 2 gemcitabine hydrochloride
40 Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus Terminated NCT00003054 Phase 2 paclitaxel
41 Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus Terminated NCT00033644 Phase 2 cisplatin;dacarbazine;doxorubicin hydrochloride;mitomycin C
42 Pazopanib for Treating Uterine Leiomyosarcoma Withdrawn NCT02378142 Phase 2 Pazopanib
43 Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery Unknown status NCT01958580 Gemcitabine Hydrochloride;Docetaxel
44 Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus Completed NCT00614835 Docetaxel plus Gemcitabine
45 Collecting Tumor Samples From Patients With Gynecological Tumors Completed NCT00897442
46 Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford Recruiting NCT01793168

Search NIH Clinical Center for Uterus Leiomyosarcoma

Genetic Tests for Uterus Leiomyosarcoma

Anatomical Context for Uterus Leiomyosarcoma

The Foundational Model of Anatomy Ontology organs/tissues related to Uterus Leiomyosarcoma:

18
The Smooth Muscle Of The Uterus

MalaCards organs/tissues related to Uterus Leiomyosarcoma:

38
Uterus, Smooth Muscle, Endothelial, Lung

Publications for Uterus Leiomyosarcoma

Articles related to Uterus Leiomyosarcoma:

# Title Authors Year
1
Epithelioid leiomyosarcoma of uterus. ( 22602833 )
2012
2
Peritoneal washing cytology findings of disseminated myxoid leiomyosarcoma of uterus: report of a case with emphasis on possible differential diagnosis. ( 12112816 )
2002

Variations for Uterus Leiomyosarcoma

Expression for Uterus Leiomyosarcoma

Search GEO for disease gene expression data for Uterus Leiomyosarcoma.

Pathways for Uterus Leiomyosarcoma

GO Terms for Uterus Leiomyosarcoma

Sources for Uterus Leiomyosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....